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Background
Riociguat, an oral soluble guanylate cyclase stimulator, is
under investigation for pulmonary hypertension treat-
ment. Cytochrome P450 (CYP)-mediated oxidative meta-
bolism is one of the major riociguat clearance pathways.
The pharmacokinetic interactions between riociguat and
ketoconazole (multi-pathway CYP and P-glycoprotein/
breast cancer resistance protein [P-gp/BCRP] inhibitor),
clarithromycin (CYP3A4 inhibitor), and midazolam
(CYP3A4 substrate) were investigated.
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Figure 1 Plasma concentrations of riociguat 0.5 mg alone or in combination with ketoconazole 400 mg.
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Methods
Three open-label, randomized, crossover studies were
performed in healthy males. In the first study, subjects
received riociguat 0.5 mg ± ketoconazole (4-day pre-
treatment with once-daily [od] ketoconazole 400 mg,
then riociguat + 1 dose of ketoconazole 400 mg) (n = 16).
In the second study, subjects received riociguat 1 mg ±
clarithromycin (4-day pretreatment with twice-daily
clarithromycin 500 mg, then riociguat + 1 dose of
clarithromycin 500 mg) (n = 14). In the third study, sub-
jects received three-times daily (tid) riociguat 2.5 mg for
3 days, then 1 day of riociguat 2.5 mg tid ± midazolam
7.5 mg (n = 24). Pharmacokinetic parameters, safety, and
tolerability were assessed.
Results
Pre- and co-treatment with ketoconazole increased rioci-
guat mean AUC by 150% and mean Cmax by 46% (Figure 1;
Table 1 The effects of ketoconazole and clarithromycin on riociguat pharmacokinetics (geometric means and
coefficients of variation)
Riociguat/ketoconazole study Riociguat/clarithromycin study
Parameter Riociguat 0.5 mg (n=16) Riociguat 0.5 mg + ketoconazole (n=16) Riociguat 1 mg (n=14) Riociguat 1 mg + clarithromycin (n=14)
GM %CV GM %CV GM %CV GM %CV
AUC (µg·h/L) 81.9 78.6 204.9 44.9 171.1 97.0 240.0 88.9
Cmax (µg/L) 9.4 29.9 13.7 19.3 20.8 37.7 21.6 33.9
t1/2 (h) 7.3 78.5 9.2 57.1 6.4 77.1 7.9 54.6
CL/f (L/h) 6.1 78.6 2.4 44.9 5.8 97.0 4.2 88.9
AUC, area under plasma concentration–time curve; CL/f, total riociguat clearance from plasma; Cmax, maximum riociguat plasma concentration; CV, coefficient of
variation; GM, geometric mean; t1/2, elimination half-life.
Figure 2 Plasma concentrations of riociguat 1 mg alone or in combination with clarithromycin 500 mg.
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Table 1). Pre- and co-treatment with clarithromycin
increased riociguat AUC by 41% without significantly
increasing Cmax (Figure 2; Table 1). Riociguat pre- and co-
treatment did not significantly alter the AUC or Cmax of
midazolam (Figure 3; Table 2). In the ketoconazole study,
adverse events (AEs) were reported in 4 (25%), 6 (38%), and
5 (31%) subjects treated with riociguat alone, riociguat +
ketoconazole, and ketoconazole alone, respectively. In the
clarithromycin study, AEs were reported in 4 (29%), 9
(64%), and 9 (64%) subjects treated with riociguat alone,
riociguat + clarithromycin, and clarithromycin alone,
respectively. In the midazolam study, AEs were reported in
20 (87%), 11 (48%), and 6 (27%) subjects treated with rioci-
guat alone, riociguat + midazolam, and midazolam alone,
respectively. The most common AEs with riociguat ± keto-
conazole, clarithromycin, and midazolam across the three
studies were headache and dyspepsia. One serious AE was
reported in the midazolam study (elevated creatine phos-
phokinase; not drug-related).
Conclusions
The combined use of riociguat with multi-pathway inhi-
bitors such as anti-mycotics (eg ketoconazole) or HIV
protease inhibitors should be avoided due to the
Figure 3 Plasma concentrations of midazolam 7.5 mg alone, and in combination with riociguat 2.5 mg. LLOQ, lower limit of quantification.
Table 2 The effects of riociguat on midazolam pharmacokinetics (geometric means and coefficients of variation)
Midazolam/riociguat study
Midazolam (n=22) Midazolam + riociguat 2.5 mg (n=22)
Parameter GM %CV GM %CV
AUC (µg·h/L) 91.1 34.3 98.2 37.0
Cmax (µg/L) 29.0 45.1 29.5 41.5
t1/2 (h) 4.5 35.9 4.3 34.9
AUC, area under plasma concentration–time curve; Cmax, maximum riociguat plasma concentration; CV, coefficient of variation; GM, geometric mean; t1/2,
elimination half-life.
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expected increase in riociguat exposure. General dose
adaptation for patients with co-medication inhibiting the
CYP3A4 pathway or the P-gp/BCRP-mediated excretion
of riociguat, beyond the dose titration concept for rioci-
guat, is not deemed necessary. Riociguat ± ketoconazole,
clarithromycin, or midazolam was generally well tolerated.
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